Melanoma Cells News and Research

RSS

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Researchers at Sydney’s Centenary Institute have taken the lead on a promising new class of drugs that may prove to be highly effective for the treatment of certain cases of melanoma.

14 Aug 2015

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.

11 Aug 2015

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Skin cancer is the most common of all cancers, and melanoma, which accounts for 2% of skin cancer cases, is responsible for nearly all skin cancer deaths. Melanoma rates in the US have been rising rapidly over the last 30 years, and although scientists have managed to identify key risk factors, melanoma's modus operandi has eluded the world of medical research.

4 Aug 2015

New phase III cancer treatment trial opens for patient with advanced melanoma

A new phase III cancer treatment trial has opened for patient enrollment that examines two treatments that work in completely different ways yet have both been shown in previous clinical trials to be effective in treating patients with advanced melanoma, the ECOG-ACRIN Cancer Research Group announced today.

22 Jul 2015

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Boston University School of Medicine researchers Neil Joseph Ganem, PhD and Anurag Singh, PhD, each have received the Jackie King Young Investigator Awards from the Melanoma Research Alliance (MRA), the largest private funder of melanoma research. Both serve as assistant professors of pharmacology & experimental therapeutics and medicine.

17 Jul 2015

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research.

1 Jul 2015

Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Researchers in the United Kingdom and Denmark have studied the "see-through" larvae of zebrafish to reveal how wound healing leads to skin cancer. Live imaging shows neutrophils, the protective inflammatory cells of the body's immune system, diverted from an induced wound to any nearby precancerous skin cells.

1 Jul 2015

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic.

24 Jun 2015

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association.

23 Jun 2015

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas.

19 Jun 2015

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine.

19 Jun 2015

Researchers find easy way to produce carbon nanoparticles that can carry drugs to targeted tissues

Researchers have found an easy way to produce carbon nanoparticles that are small enough to evade the body's immune system, reflect light in the near-infrared range for easy detection, and carry payloads of pharmaceutical drugs to targeted tissues.

19 Jun 2015

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell.

18 Jun 2015

Presence of collagen in tumor microenvironment can be either good or bad

The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.

21 May 2015

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

Subpopulation of tumor cells make melanoma aggressive

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures.

10 Apr 2015

Melanoma Cells News and Research

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Researchers create new cell screening method for immunotherapy cancer treatments

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

New phase III cancer treatment trial opens for patient with advanced melanoma

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Drugs used against impotence does not increase risk of malignant melanoma

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Researchers find easy way to produce carbon nanoparticles that can carry drugs to targeted tissues

Melanoma patients with high levels of H2A.Z.2 protein less likely to survive

Presence of collagen in tumor microenvironment can be either good or bad

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Scientists uncover new pharmaceutical strategy for treating melanoma

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Subpopulation of tumor cells make melanoma aggressive

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News